Coagulation and Fibrinolytic Disturbances in Women with Polycystic Ovary Syndrome

被引:71
|
作者
Manneras-Holm, Louise [1 ]
Baghaei, Fariba [2 ]
Holm, Goran [3 ]
Janson, Per Olof [4 ]
Ohlsson, Claes [5 ]
Lonn, Malin [6 ]
Stener-Victorin, Elisabet [1 ,7 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Dept Physiol, Inst Neurosci & Physiol, SE-40530 Gothenburg, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Internal Med, S-41345 Gothenburg, Sweden
[3] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Metab & Cardiovasc Res, S-41345 Gothenburg, Sweden
[4] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Obstet & Gynecol, S-41345 Gothenburg, Sweden
[5] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, S-40530 Gothenburg, Sweden
[6] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Clin Chem & Transfus Med, S-40530 Gothenburg, Sweden
[7] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Harbin 150040, Peoples R China
来源
基金
英国医学研究理事会;
关键词
PLASMINOGEN-ACTIVATOR INHIBITOR-1; CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; RISK; FIBRINOGEN; PATHOPHYSIOLOGY; INFLAMMATION; ADIPOCYTE; MARKERS; OBESE;
D O I
10.1210/jc.2010-2279
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Studies of fibrinolysis/coagulation status in women with polycystic ovary syndrome (PCOS) are contradictory. Objectives: The aim of the study was to investigate whether women with PCOS have disturbed circulating levels of fibrinolysis/coagulation markers and, if so, whether the disturbances are related to hemodynamics, metabolic variables, sex steroids, SHBG, lipids, and inflammatory variables in women with PCOS. Design/Main Outcome Measures: Anthropometric variables, hemodynamics, circulating hemostatic and inflammatory markers, and serum lipid profile were measured in women with untreated PCOS (n = 74) and controls (n = 31). Results: After adjustments for age and body mass index (BMI), circulating plasminogen activator inhibitor 1 (PAI-1) activity and fibrinogen levels were higher in women with PCOS than controls; lipid profile, blood pressure, and levels of D-dimer, von Willebrand factor, factor VIII, tissue plasminogen activator, and inflammatory markers were comparable in the two groups. In multiple linear regression analyses including women with PCOS, low SHBG and high insulin predicted high PAI-1 activity (R-2 = 0.526; P < 0.001); elevated high-sensitivity C-reactive protein and soluble E-selectin in combination with heart rate predicted high fibrinogen (R-2 = 0.333; P < 0.001). Differences in PAI-1 activity were not significant after adjustments for age, BMI, SHBG, and insulin. Conclusions: PCOS is characterized by a prothrombotic state, as reflected by increased PAI-1 activity and fibrinogen, without signs of dyslipidemia or a proinflammatory state. Low SHBG and high insulin may partly explain the BMI-independent difference in PAI-1 activity between women with PCOS and controls. High-sensitivity C-reactive protein and E-selectin may be involved in regulating fibrinogen in PCOS. (J Clin Endocrinol Metab 96: 1068-1076, 2011)
引用
收藏
页码:1068 / 1076
页数:9
相关论文
共 50 条
  • [31] Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome
    Hong, So-hyeon
    Sung, Yeon-Ah
    Hong, Young Sun
    Jeong, Kyungah
    Chung, Hyewon
    Lee, Hyejin
    CLINICAL ENDOCRINOLOGY, 2017, 87 (04) : 375 - 380
  • [32] Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity
    Slopien, R.
    Lewandowski, K.
    Kolacz, E.
    Zawilska, K.
    Warenik-Szymankiewicz, A.
    GYNECOLOGICAL ENDOCRINOLOGY, 2006, 22 (11) : 651 - 654
  • [33] Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome
    Belli, SH
    Graffigna, MN
    Oneto, A
    Otero, P
    Schurman, L
    Levalle, OA
    FERTILITY AND STERILITY, 2004, 81 (03) : 624 - 629
  • [34] Screening women with polycystic ovary syndrome for metabolic syndrome
    Dokras, A
    Bochner, M
    Hollinrake, E
    Markham, S
    VanVoorhis, B
    Jagasia, DH
    OBSTETRICS AND GYNECOLOGY, 2005, 106 (01): : 131 - 137
  • [35] THE ROLE OF HYPERINSULINEMIA IN THE DEVELOPMENT OF LIPID DISTURBANCES IN NONOBESE AND OBESE WOMEN WITH THE POLYCYSTIC-OVARY-SYNDROME
    SLOWINSKASRZEDNICKA, J
    ZGLICZYNSKI, S
    WIERZBICKI, M
    SRZEDNICKI, M
    STOPINSKAGLUSZAK, U
    ZGLICZYNSKI, W
    SOSZYNSKI, P
    CHOTKOWSKA, E
    BEDNARSKA, M
    SADOWSKI, Z
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1991, 14 (07) : 569 - 575
  • [36] Prevalence of metabolic syndrome in women with polycystic ovary syndrome
    Panidis, Dimitrios
    Macut, Djuro
    Tziomalos, Konstantinos
    Papadakis, Efstathios
    Mikhailidis, Konstantinos
    Kandaraki, Eleni A.
    Tsourdi, Elena A.
    Tantanasis, Theoharis
    Mavromatidis, George
    Katsikis, Ilias
    CLINICAL ENDOCRINOLOGY, 2013, 78 (04) : 586 - 592
  • [37] METABOLIC SYNDROME IN POLYCYSTIC OVARY SYNDROME TUNISIAN WOMEN
    Smaoui, Fatma
    Chaabouni, Khansa
    Elleuch, Aida
    Boudaya, Mariem
    Mezghani, Chema
    Chaabene, Kais
    Frikha, Madiha
    Ayadi, Fatma
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL 1) : E271 - E271
  • [38] Stress in women - Metabolic syndrome and polycystic ovary syndrome
    Diamanti-Kandarakis, Evanthia
    Economou, Frangiskos
    STRESS, OBESITY, AND METABOLIC SYNDROME, 2006, 1083 : 54 - 62
  • [39] Prevalence of metabolic syndrome in women with polycystic ovary syndrome
    Popovic, B.
    Macut, D.
    Bozic, I.
    Petakov, M.
    Ognjanovic, S.
    Isailovic, T.
    Damjanovic, S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 426 - 427
  • [40] Prevalence of the metabolic syndrome in women with polycystic ovary syndrome
    Bregieiro Fernandes Costa, Laura Olinda
    Ribeiro Viana, Aline de Oliveira
    de Oliveira, Monica
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2007, 29 (01): : 10 - 17